An uncertain role for p53 gene alterations in human prostate cancers

Cancer Research

Volumn 56, Issue 16, 1996, Pages 3814-3822

  Brooks, James D ^a   Bova, G Steven ^a   Ewing, Charles M ^a   Piantadosi, Steven ^a   Carter, Bob S ^a   Robinson, John C ^a   Epstein, Jonathan I ^a   Isaacs, William B ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CHROMOSOME 17P; CHROMOSOME LOSS; CONTROLLED STUDY; DNA SEQUENCE; GENE LOSS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENCE RISK; SINGLE STRAND CONFORMATION POLYMORPHISM;

BASE SEQUENCE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029783149     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Adders, T. W., Schalken, J. A , Epstein, J I., and Isaacs, W. B. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl. Acad. Sci USA, 87: 8751-8755, 1990
2. Isaacs, W. B , Carter, B. S , and Ewing, C. M Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles Cancer Res , 51: 4716-4720, 1991
3. Bartek, J , Iggo, R , Gannon, J., and Lane, D P. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines Oncogene, 5: 893-899, 1990
4. Visakorpi, T., Kallioniemi, O P., Heikkinen, A., Koivula, T , and Isola, J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883-887, 1992
5. Bauer, J. J., Sesterhenn, I. A , Mostofi, K. F , McLeod, D. G., Srivastava, S . and Moul, J. W. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy Clin. Cancer Res , 1: 1295-1300, 1995.
6. Thompson, S. J., Mellon, K , Charlton, R. G , Marsh, C., Robinson, M., and Neal, D E. p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J. Urol , 69: 609-613, 1992
7. Van Veldhuizen, P. J., Sadasivan, R., Garcia, F., Austenfeld, M. S., and Stephens, R L. Mutant p53 expression in prostate carcinoma. Prostate, 22: 23-30, 1993.
8. 0 prostatic adenocarcinoma Int J Cancer, 58: 303-308, 1994
9. Aprikian, A G , Sarkis, A. S , Fair, W R , Zhang, Z. F , Fuks, Z., and Cordon-Cardo, C Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma J Urol, 151: 1276-1280, 1994.
10. Bookstein, R., MacGrogan, D , Hilsenbeck, S. G , Sharkey, F , and Allred, D C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res , 53: 3369-3373, 1993.
11. Navone, N M , Troncoso, P., Pisters, L. L , Goodrow, T. L., Palmer, J L., Nichols, W W., Von Eschenbach, A. C., and Conti, C J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma J. Natl Cancer Inst., 85: 1657-1669, 1993.
12. Heidenberg, H. B , Sesterhenn, I A., Gaddipati, J. P , Weghorst, C. M , Buzard, G S., Moul, J. W., and Srivastava, S Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol , 154: 414-421, 1995.
13. Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T L., Yang, G., Slawin, K. M , Wheeler, T. M , Scardino, P. T., and Thompson, T. C. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res , 1: 1111-1118, 1995
14. Dinjens, W. N. M , Van Der Weiden, M M., Schroeder, F. H , Bosman, F. T., and Trapman, J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J. Cancer, 56: 630-633, 1994.
15. Voeller, H J , Sugars, L. Y , Pretlow, T., and Gelmann, E. P. p53 oncogene mutations in human prostate cancer specimens. J. Urol , 151: 492-495, 1994
16. Effert, P. J., McCoy, R. H , Walther, P. J., and Liu, E T. p53 gene alterations in human prostate carcinoma J. Urol., 150: 257-261, 1993.
17. Uchida, T., Wada, C , Shitara, T., Egawa, S , and Koshiba, K. Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer Br J. Cancer, 68 751-755, 1993.
18. Chi, S. G., deVere White, R. W , Meyers, F. J , Siders, D B., Lee, F., and Gummerlock, P. H. p53 in prostate cancer frequent expressed transition mutations. J Natl. Cancer Inst., 86: 926-933, 1994
19. Kubota, Y , Shuin, T., Uemura, H., Fujinami, K., Miyamoto, H., Torigoe, S., Dobashi, Y., Kitamura, H., Iwasaki, Y., Danenberg, K., and Danenberg, P. V Tumor suppressor gene p53 mutations in human prostate cancer. Prostate, 27: 18-24, 1995.
20. Lu, X., Park, S. H., Thompson, T. C., and Lane, D P. ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without mutation. Cell, 70: 153-161, 1992.
21. Thompson, T. C., Park, S H., Timme, T L , Ren, C., Eastham, J A., Donehower, L A, Bradley, A, Kadmon, D., and Yang, G. Loss of p53 function leads to metastasis in ras + mvc-initiated mouse prostate cancer. Oncogene, 10: 869-879, 1995.
22. Eastham, J. A., Hall, S. J , Sehgal, I., Wang, J , Timme, T. L., Yang, G , Connell-Crowley, L., Elledge, S. J , Zhang, W W., Harper, J W., and Thompson, T C. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55: 5151-5155, 1995
23. Levine, A. J., Momand, J,. and Findlay, C. A. The p53 tumor suppressor gene Nature (Lond.), 351: 453-456, 1991.
24. Kunimi, K., Bergerheim, U S. R., Larsson, I L , Ekman, P., and Collins, V. P. Allelotyping of human prostatic adenocarcinoma. Genomics, 11: 530-541, 1991.
25. Macoska, J A., Powell, I J., Sakr, W., and Lane, M. A. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J. Urol , 147: 1142-1146, 1992.
26. Brewster, S. F , Browne, S., and Brown, K. W. Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor loci in human prostatic carcinoma. J. Urol , 151: 1073-1077, 1994.
27. Schroder, F. H , Hermanek, P., Denis, L., Fair, W R., Gospodarowicz, M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer Prostate, 4 (Suppl): 129-138, 1992
28. Mellinger, G. T , Gleason, D., and Bailar, J. The histology and prognosis of prostatic cancer J. Urol., 97: 331-337, 1967
29. Bova, G. S., Carter, B. S , Bussemakers, M. J. G , Emi, M., Fujiwara, Y , Kyprianou, N., Jacobs, S. C., Robinson, J. C , Epstein, J. I , Walsh, P. C., and Isaacs, W. B. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer Cancer Res., 53, 3869-3873, 1993
30. Burton, K. Determination of DNA concentration with diphenylamine. Methods Enzymol , 12B: 163-166, 1968
31. Brooks, J. D., Bova, G. S , Marshall, F. F., and Isaacs, W B. Tumor suppressor gene allelic loss in human renal cancers. J. Urol., 150: 1278-1283, 1993.
32. Chumakov, P M., and Jenkins, J. R. BstNI/NctI polymorphism of the human p53 gene (TP53) Nucleic Acids Res., 19: 6969, 1991
33. Orita, M., Iwahana, H , Kanazawa, H., Hayashi, K., and Sekiya, T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl. Acad. Sci. USA, 86: 2766-2770, 1989.
34. Sidransky, D., Von Eschenbach, A., Tsai, Y C , Jones, P., Summerhayes, I., Marshall, F., Paul, M , Green, P., Hamilton, S. R., Frost, P , and Vogelstein, B. Identification of p53 gene mutations in bladder cancers and urine samples Science (Washington DC), 252: 706-709, 1991.
35. Kaplan, E L , and Meier, P. Nonparametric estimation from incomplete observations J Am. Stat. Assoc., 53: 457-481, 1958.
36. Cox, D. R Regression models and life tables. J. R. Stat. Soc. Ser. B, 34: 187-220, 1972.
37. Davidoff, A M., Humphrey, P. A., Iglehart, J. D , and Marks, J. R. Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. USA, 88: 5006-5010, 1991
38. Deng, G., Chen, L.-C., Schott, D. R., Thor, A., Bhargava, V., Ljung, B-M., Chew, K , and Smith, H S. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res , 54: 499-505, 1994.
39. Uchida, T., Wada, C., Ishida, H , Wang, C., Egawa, S., Yokoyama, E., Kameya, T., and Koshiba, K p53 mutations and prognosis in bladder tumors. J. Urol , 153: 1097-1104, 1995.
40. Chang, F., Syrjänen, S., and Syrjänen, K. Implications of the p53 tumor-suppressor gene in clinical oncology J Clin. Oncol., 13: 1009-1022, 1995.
41. Ahomadegbe, J C., Barrois, M., LeBihan, M L, Douc-Rasy, S. Duvillard, P., Armand, J P., and Riou, G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 10: 1217-1227, 1995.
42. Saxena, A., Clark, W. C., Robertson, J. T., Ikejiri, B., Oldfield, E. H., and Ali, I. U Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astocytomas. Cancer Res , 52: 6716-6721, 1992.
43. Vogan, K., Bernstein, M., Leclerc, J. M., Brisson, L., Brossard, J., Brodeur, G M , Pelletier, J., and Gros, P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res., 53: 5269-5273, 1993.
44. Phillips, N J , Ziegler, M. R., Radford, D. M., Fair, K. L., Steinbrueck, T., Xynos, F P., and Donis-Keller, H. Allelic deletion on chromosome 17p13 3 in early ovarian cancer Cancer Res , 56: 606-611, 1996
45. Brooks, J. D , Bova, G. S., and Isaacs, W. B. Retinoblastoma gene allelic loss in human prostate cancers. Prostate, 26: 35-39, 1995
46. Esrig, D., Elmajian, D , Groshen, S., Freeman, J A., Stein J. P , Chen, S-C , Nichols, P. W., Skinner, D. G , Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
47. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C , Melamed, J., Zhang, Z-F., Sheinfeld, J , Fair, W R , Herr, H. W , and Reuter, V. E Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol , 152: 388-392, 1994
48. Grosse, A. E., Tobin, A A , Eastham, J. A., Slawin, K. M., Wheeler, T. M., Scardino, P. T , and Thompson T. C Clonal expansion of p53 mutations at metastatic sites in clinical prostate cancer: an analysis using TA-SSCP (Abstract 270) J Urol., 153 (Suppl): 471A, 1995.
49. Prendergast, N. J., Atkins, M. R , Schatte, E. C , Paulson, D. F., and Walther, P. J. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostatic adenocarcinoma. J Urol., 153: 1685-1692, 1996
50. Vogelstein, B , Fearon, E. R , Kern, S. E., Hamilton, S R., Preisinger, A. C , Nakamura, Y , and White, R. Allelotype of colorectal carcinomas. Science (Washington DC), 244: 207-211, 1989